- Article
Prediction of 177Lu-DOTATATE Therapy Outcomes in Neuroendocrine Tumor Patients Using Semi-Automatic Tumor Delineation on 68Ga-DOTATATE PET/CT
- Hwan Lee,
- Sarit T. Kipnis,
- Remy Niman,
- Sophia R. O’Brien,
- Jennifer R. Eads,
- Bryson W. Katona and
- Daniel A. Pryma
Background: Treatment of metastatic neuroendocrine tumors (NET) with 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) results in favorable response only in a subset of patients. We investigated the prognostic value of quantitative pre-trea...